Editorial

Editorial Revista ION 33(1) - 2020Editorial Revista ION 33(1) - 2020Editorial Revista ION 33(1) - 202

Reconocimiento

Agradecimento - Revista ION 33(1) - 2020Acknowledgments - Revista ION 33(1) - 2020Reconocimiento - Revista ION 33(1) - 202

Editorial

Editorial Revista ION 33(2) - 2020Editorial Revista ION 33(2) - 2020Editorial Revista ION 33(2) - 202

Reconocimiento

Reconocimiento - Revista ION 32(2) - 2019Acknowledgments - Revista ION 32(2) - 2019Agradecimento - Revista ION 32(2) - 201

Editorial

Editorial Revista ION 32(2) - 2019Editorial Revista ION 32(2) - 2019Editorial Revista ION 32(2) - 201

Structural and microstructural characterization of tin(II) oxide useful as anode material in lithium rechargeable batteries obtained from a different synthesis route at room temperature

Monthly market at Pinsk. Garlic in strings of one foot in length, cost 50 gr. Each. The men in the picture are all wearing boots or shoes. The women are bare footed. This is often the case in Poland. The men rarely go bare footed. October 3, 1934.P1766; 10-34GrayscaleLouise A. Boyd, Box 53

Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome associated with COVID-19: An Emulated Target Trial Analysis.

RATIONALE: Whether COVID patients may benefit from extracorporeal membrane oxygenation (ECMO) compared with conventional invasive mechanical ventilation (IMV) remains unknown. OBJECTIVES: To estimate the effect of ECMO on 90-Day mortality vs IMV only Methods: Among 4,244 critically ill adult patients with COVID-19 included in a multicenter cohort study, we emulated a target trial comparing the treatment strategies of initiating ECMO vs. no ECMO within 7 days of IMV in patients with severe acute respiratory distress syndrome (PaO2/FiO2 <80 or PaCO2 ≥60 mmHg). We controlled for confounding using a multivariable Cox model based on predefined variables. MAIN RESULTS: 1,235 patients met the full eligibility criteria for the emulated trial, among whom 164 patients initiated ECMO. The ECMO strategy had a higher survival probability at Day-7 from the onset of eligibility criteria (87% vs 83%, risk difference: 4%, 95% CI 0;9%) which decreased during follow-up (survival at Day-90: 63% vs 65%, risk difference: -2%, 95% CI -10;5%). However, ECMO was associated with higher survival when performed in high-volume ECMO centers or in regions where a specific ECMO network organization was set up to handle high demand, and when initiated within the first 4 days of MV and in profoundly hypoxemic patients. CONCLUSIONS: In an emulated trial based on a nationwide COVID-19 cohort, we found differential survival over time of an ECMO compared with a no-ECMO strategy. However, ECMO was consistently associated with better outcomes when performed in high-volume centers and in regions with ECMO capacities specifically organized to handle high demand. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/)